Tech Company Financing Transactions
Codagenix Funding Round
Codagenix closed a $20 million Series B financing round on 1/14/2020. Investors included Adjuvant Capital, Euclidean Capital and Topspin Partners.
Transaction Overview
Company Name
Announced On
1/14/2020
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the further clinical development of its live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine and an oncolytic virus therapy for triple negative breast cancer (TNBC).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Bioscience Park Dr.
Farmingdale, NY 11735
USA
Farmingdale, NY 11735
USA
Phone
Undisclosed
Website
Email Address
Overview
Codagenix utilizes our breakthrough platform technology termed SAVE (Synthetic Attenuated Virus Engineering) to construct live-attenuated viral vaccines against multiple targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Coleman
Chief Medical Officer
Sybil Tasker
President
Steffen Mueller
VP - Bus. Development
Anna Kushnir
Browse more venture capital transactions:
Prev: 1/14/2020: Kyverna Therapeutics venture capital transaction
Next: 1/14/2020: Treadwell Therapeutics venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs